论文部分内容阅读
目的探讨原发肿瘤切除和靶向治疗在Ⅳ期乳腺癌治疗中的作用。方法收集Ⅳ期乳腺癌患者300例,按照不同的治疗方案分为试验组和对照组,每组150例。所有患者均采用改良根治术进行治疗,试验组患者加用对甲苯磺酰胺注射液进行靶向治疗。结果试验组和对照组患者的有效率分别为73.3%和46.7%,差异有统计学意义(P<0.05)。两组患者的主要不良反应为Ⅰ~Ⅱ级的骨髓抑制、消化道反应和呕吐等,两组间差异无统计学意义(P>0.05)。试验组和对照组患者的1年生存率分别为90.7%和73.3%,两组间差异有统计学意义(P<0.05)。结论原发肿瘤改良根治术联合靶向药物治疗Ⅳ期乳腺癌能够提高疗效和生存时间,降低不良反应的发生。
Objective To investigate the role of primary tumor resection and targeted therapy in the treatment of stage Ⅳ breast cancer. Methods 300 patients with stage Ⅳ breast cancer were collected and divided into experimental group and control group according to different treatment plans, with 150 cases in each group. All patients were treated with modified radical mastectomy. Patients in the test group were treated with p-toluenesulfonamide injection for targeted therapy. Results The effective rates of the experimental group and the control group were 73.3% and 46.7%, respectively, with significant difference (P <0.05). The main adverse reactions of the two groups were grade Ⅰ ~ Ⅱ myelosuppression, gastrointestinal reaction and vomiting. There was no significant difference between the two groups (P> 0.05). The 1-year survival rates of trial group and control group were 90.7% and 73.3%, respectively, with significant difference between the two groups (P <0.05). Conclusion Modified radical mastectomy combined with targeted drug treatment of stage Ⅳ breast cancer can improve the efficacy and survival time, reduce the incidence of adverse reactions.